Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ferrara

Showing results (551-560 of 566) with videos related to

Pageof 57
Sort By:
Blood|July 5, 2024
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHDYu Akahoshi, Nikolaos Spyrou, Daniela Weber, et al.
Blood|September 15, 2016
Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factorsShernan G Holtan, Nandita Khera, John E Levine, et al.
Blood Advances|February 7, 2024
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysisYu Akahoshi, Nikolaos Spyrou, Matthias Hoepting, et al.
Blood Advances|April 19, 2024
Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHDAaron Etra, Najla El Jurdi, Nikolaos Katsivelos, et al.
Blood|March 17, 2018
MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHDHannah Major-Monfried, Anne S Renteria, Attaphol Pawarode, et al.
Blood Advances|May 26, 2023
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host diseaseMonzr M Al Malki, Kaitlyn London, Janna Baez, et al.
Blood Advances|June 14, 2023
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHDYu Akahoshi, Nikolaos Spyrou, William J Hogan, et al.
Blood Advances|August 15, 2025
The MAGIC Composite Response: A Novel Endpoint Integrating Clinical and Biomarker Parameters for Acute GVHDYu Akahoshi, Joseph Portelli, Nikolaos Katsivelos, et al.
Transplantation and Cellular Therapy|February 6, 2024
A Day 14 Endpoint for Acute GVHD Clinical TrialsNikolaos Spyrou, Yu Akahoshi, Steven Kowalyk, et al.
Blood Advances|August 9, 2018
Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802Shernan G Holtan, Todd E DeFor, Angela Panoskaltsis-Mortari, et al.
Pageof 57

Showing results (551-560 of 566) with videos related to

Sort By:
Pageof 57
Blood|July 5, 2024
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHDYu Akahoshi, Nikolaos Spyrou, Daniela Weber, et al.
Blood|September 15, 2016
Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factorsShernan G Holtan, Nandita Khera, John E Levine, et al.
Blood Advances|February 7, 2024
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysisYu Akahoshi, Nikolaos Spyrou, Matthias Hoepting, et al.
Blood Advances|April 19, 2024
Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHDAaron Etra, Najla El Jurdi, Nikolaos Katsivelos, et al.
Blood|March 17, 2018
MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHDHannah Major-Monfried, Anne S Renteria, Attaphol Pawarode, et al.
Blood Advances|May 26, 2023
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host diseaseMonzr M Al Malki, Kaitlyn London, Janna Baez, et al.
Blood Advances|June 14, 2023
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHDYu Akahoshi, Nikolaos Spyrou, William J Hogan, et al.
Blood Advances|August 15, 2025
The MAGIC Composite Response: A Novel Endpoint Integrating Clinical and Biomarker Parameters for Acute GVHDYu Akahoshi, Joseph Portelli, Nikolaos Katsivelos, et al.
Transplantation and Cellular Therapy|February 6, 2024
A Day 14 Endpoint for Acute GVHD Clinical TrialsNikolaos Spyrou, Yu Akahoshi, Steven Kowalyk, et al.
Blood Advances|August 9, 2018
Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802Shernan G Holtan, Todd E DeFor, Angela Panoskaltsis-Mortari, et al.
Pageof 57